Erratum: Development of a subcutaneous formulation for trastuzumab - Nonclinical and clinical bridging approach to the approved intravenous dosing regimen (Drug Research (2012) 62 (401-409) DOI:10.1055/s-0032-1321831)

Drug Research

Volumn 63, Issue 11, 2013, Pages 602-

  Bittner, B ^a   Richter, W F ^a   Hourcade Potelleret, F ^a   McIntyre, C ^a   Herting, F ^b   Zepeda, M L ^c   Schmidt, J ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c Halozyme Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERRATUM; ERROR;

EID: 84888874563     PISSN: 21949379     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0033-1357211     Document Type: Erratum

References (0)